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While there are many published ran-domised control trials assessing the
benefits of therapy for postmenopausal
osteoporosis.' theseare limited in men,
In order to develop the following guide-
lines for the management of osteoporosis in
men. allpublished manuscripts andabstracts
over the past20 years. relating to the treat-
ment of osteoporosis in men were enlisted
through a systematic search of Medline,
Current Contents, CINAHL and Cochrane
Library. We also scanned the bibliographies'
of included studies for additional references
and abstracts presented at the Annual
Meeting of the American Society for Bone
andMineral Research and the International
Bone and Mioeral Society. Only publica-
tions relating to the treatment of
osteoporosis in men were evaluated. By
using the level of evidence according to the
NH&MRC criteria (Table 1). an algorithm
was devised for the most appropriate treat-
ments ofosteoporosis inmen (FIgure I).
The following treatment strategies are
presented according to the level of evi-
dence based on randomised controlled
trials (RCTs). While only studies pertain-
ing to the treatment of osteoporosis in
men were sought. this has occasionally
proven difficult and where specified. the
combined treatment data for 'both men
and women has been presented. Studies
relatingto the treatment of glucocorticoid
induced osteoporosis in men are dis-
cussed elsewhere in this journal.
General measures
These include recommendations for
lifestyle modification discussed in the pre-
vious article (pp. 781-785). One
systematic review (15 RCTs, 1054
patients, predominantly women, EI).
found that nutritional supplementation
(oral protein and energv feeds) reduced
unfavourable outcomes after a hip
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Table l:~Levels of evidence
according to' the NH&MRC
• Level 1 (El) evidence obtained from
a systematic review of all relevant
randomised controlled trials.
_.- _._----_ __ .
• Level 2 (E2) evidence obtained from
at least one properly designed
randomised control trial.
• Level 3 (E3) evidence obtained from
a well designed pseudo randomised
controlled trial.
• Level 4 (E4) evidence obtained from
case series, either post-test or
pre-test and post-test
Clinical presentation
fracture. There are no reports relating to
nutritional supplementation and either
changes in hone mineral density (BMD)
or fracture rates in men.
Falls prevention and rehabilitation
programs
These may be beneficial for elderly men
with multiple risk factors for falling. The
overall evidence (18 RCTs, predominantly
women, OR~L72: 0.78-3.75) for effective-
ness of geriatric orthopaedic rehabilitation
units is inconclusive (El ).' A recent analysis
suggested that there is inadequate evidence
for the effectiveness of single interventions
Investigation
such as exercise alone or health education
classesfor the prevention offalls (El).'
Hip protectors
Most hip fractures occur as a result of a
fall or other traumatic event resulting in
direct impact onto osteoporotic hone. Hip
protectors reduce the risk of hip fracture
within a selected population (frail and
elderly) at high risk of sustaining a hip
fracture. The cost effectiveness is unclear.
Acceptability by the users of the pro-
tector remains a problem, with poor tong


















· • corticosteroid use'
• family history of osteoporotlc
fracture .
· • low body'weight .
: • smoking
.-•.recurreht falls"
Other risk factors for fracture
• llfestyle factors: low calcium
intake, physical inactivity,
smoking, excess alcohol



















up in 2-5 years
Figure 1. Osteoporosis clinical guidelines for men
# If hypogonadism is present, decadurabolin is inappropriate
t Oalcltrlol not recommended as treatment.
'" See article 'Men and osteoporosis', Table 2. p. 782.
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Risedronate
Risedronate is the most potent of the four
bisphosphonates listed. There is one
RCT" (E2), assessing the role of rise-
dronate in glucocorticoid induced
osteoporosis.
• Men with osteoporosis who show
inadequate response to therapy
• Men who experience problems or
side-effects with treatment
• Men who present with an acute







BMD increased over a 1-3 year treatment
period by 6-10% and 2.5-5.0%, respec-
tively. There is no published BMD data
comparing the effects of alendronate 10 Referral to specialist bone centres is
mg daily to alendronate 70 mg once appropriate in the following
weekly on BMD in men with osteoporosis. circumstances:
Alendronate has been associated With--...."Menwithcisteopb·roslscwhochave~~·~- .
dyspepsia, abdominal pains and' compiex·medical conditions"
oesophageal ulceration in women, but • Young men «50 years) who present
. . _ ~__ with severe osteoporosisthis does not appear to present a major -. :-.. ,._- ce, C-O"---CC-.C:"=',,",O·'.'CC.-C .
problem in men." • Men who present with history of
numerous or recurrent fractures
There are no RCTs assessing the antifrac-
ture efficacy of cyclical etidronate in men
with osteoporosis, except in glucocorti-
coid induced osteoporosis (E2)." There
are nine RCTs"'''-'' (300 subjects, in open
labelled studies with no case controls, E3)
in men with osteoporosis treated with
cyclical etidronate. In all studies, signifi-
cant increases in spinal BMD (3-9%)
were noted over a 2-5 year treatment
period, without consistent changes in
femoral neck BMD.
Etidronate is used in a cyclical
regimen (400 mg daily for 14 days of
every three monthly cycle) so as to
prevent a mineralisation defect which.
.. Calcium and vitamin D
may occur if administered continuously.
It has been'reported to.cause mild"in"'fl"'a"'m,..-__C=a"'lc"ium and vitamin D are weakly
mation in the lower, but not upper antiresorptive. There are no RCTs
gastrointestinal tract." assessing the antifracture efficacy of
calcium and vitamin D3 in men with
osteoporosis. There are three RCTs2~30
Pamidronate (Aredia) is approved for the _.._(456 .treated and 456 controls) assessing
treatment of osteoporosis in men with therole of-calcium and vitamin D on
myelomatous bone disease (S-100 fracture prevention in 'healthy' elderly
scheme). There is one RCT" (E2) per- men (E2). In all three, the primary end-
formed in patients (108 pamidronate point was' spinal fractures.
treated men) with lytic myelomatous Unfortunately, when·the data was
bone disease, demonstrating significant analysed separately for men, the benefi-
reductions in skeletal events (pathological cial effect on fracture reduction was lost
fractures, hypercalcaemia and the need due to low fracture rates. Moreover, in
for radiotherapy or surgical intervention). one of the RCTs~ (333 men randomised
Other RCTs demonstrating increases in to vitamin D3 400 units daily and 329 to .
BMD with pamidronate have been per- placebo) fracture rates were significantly
formed in men with osteoporosis affected by a large proportion of the men
receiving glucocorticoid therapy and who were receiving vitamin supplements
undergoing transplantation (E4).u before enrolment.
In a study of 392 men and 1409
women aged 70 years and older, hip pro-
tectors significantly reduced the risk of
. hip fractures (13 subjects in the hip pro-
tector group had a hip fracture, as
compared with 67 subjects in the control




Bisphosphonates are potent inhibitors of
bone resorption." There are numerous
studies reporting the benefits of alen-
dronate and risedronate for the treatment
of postmenopausal osteoporosis (ElF'
Published data in men has only recently
become available. Currently four bisphos-
phonates are available for the treatment
of osteoporosis inmen in Australia.
Alendronate
Alendronate (Fosamax) is an amino-
bisphosphonate, which does not impair
mineralisation. There are two RCTs
assessing the antifracture efficacy of
alendronate in men." In one RCT" (146
alendronate treated and 95 controls,
, aged 31-87 years, randomised for two
years, E2) alendronate 10 mg daily sig-
nificantly reduced spinal fracture rates
(0.8 versus 7.1%; P=0.02). All subjects
received daily calcium (500 mg) and
vitamin D3 (400-450 JU). In the other
RCT' (68 alendronate treated and 65
alfacalcidol treated men, two year open
label randomised study, E3) there were
five subjects with spinal fractures in
the alendronate treated group and 10
in the alfacalcidol treated group
(P=0.04). These are the only puhlished
studies powered adequately to demon-
strate antifracture efficacy in men with
osteoporosis (defined as a BMD
t-score <-2.5).
To our knowledge, there are six
RCTs'" (348 alendronate treated and 277
controls, E3) evaluating the effects of alen-
dronate on BMD in men with
osteoporosis. Spinal and femoral neck
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Administering testosterone
Calcitonin by subcutaneous injection
(100 units every three weeks) reduced
bone turnover in 12 castrated "men in
one RCT" (E3) and increas~d total body
Current evidence suggests that cal--· - te-stosterone--Hle~rap)i (intramuscular
citriol is unlikely to be beneficial for 'inie'ctionfiil-me-nwith"osteoporotic
treating men with idiopathic osteoporosis, spinal fractures and normal testosterone
Furthermore, there is an associated risk levels. Six months of therapy resulted in
of hypercalcaemia and hypercalciuria a 5% increase in spinal BMD (E4).
with doses of 0.5 ~g dailyor.more."---.~-~-,-.~-Ther"-"re-eight_RCTs''''-p6 men,
aged 65 years and older, E2) assessing
the role of testosterone therapy (injec-
tion, transdermal or sublingual) in
normal elderly men. Decreases in fat
free mass accompanied by increases in
lean mass were apparent after a 3-36
month treatment period. No significant
changes in muscle strength were
observed, while only modest increases in
spinal BMD «2%) were reported.
Other weaker androgens such as nan-
drolone (one RCT,'" 21 men) have been
studied in eugonadal men with osteo-
porotic fractures but without any
beneficial effect (E4).
In men with hypogonadism
Testosterone
Testosterone replacement can be ade-
There are two RCT"'" (21 men in one quately achieved by the transdermal
study and eight in another, aged 19-53 route (androderm patch 12.5 mg twice
years, E4), demonstrating the effects of daily), intramuscular injections (depot
testosterone replacement in men with testosterone or sustanon 250 mg every
delayed puberty (idiopathichypcgo- 2-3 weeks) or by subcutaneous implants
nadotrophic hypogonadism): Significant (600 mg every 4-6 months}.":"
increases in both-corticahmd-trabeeular-'FeshlSteronetherapy is available for
bone density was observed, with maximal men with proven androgen deficiency
responses occurring in those whose epi- due to testicular or pituitary origin (PBS
physeshad not yet fused. authority required). While all forms of
There are six RCTs''''' (73 men with testosterone supplements appear to be
acquired hypogonadism,E3rassessiiig'ttie'~ well tolerated, their long term safety
role of testosterone replacement (intra. remains unclear. The risk of prostatic
muscular injection) on BMD in disease in eugonadal men is uncertain."
hypogonadal men. Significant increases in Due to reported cases of prostatic carci-
spinal BMD as measured by both dual noma occurrmg with prolonged
energy X-ray absorptiometry (DXA) and testosterone therapy, regular digital
quantitative computed tomography examination of the prostate and moni-
(OCT) (5-15%) and increases in muscle toring of serum prostate specific antigen
strength were observed over 18-24 activities is required.
months. No significant changes in cortical
BMD were noted. Other therapies
In men with normal testosterone levels
There is only one RCT" (21 men aged
34-73 years, E4) assessing the role of
Up to 16% of men with spinal fractures
have evidence of hypogonadism."
Testosterone therapy and its effect on
BMD are largelydependent on:
• gonadal and growthstatus of the
individual
• the duration of pre-existing
hypogonadism
'. the degree of osteopoenia and
• the duration of testosterone
therapy."....."
There are no published studies demon-
strating antifracture efficacy with
prolonged testosterone therapy,
Calcitriol (rocaltrol)
There are two RCTs"'''' (123 treated
and 127 control. E2) demonstrating a
positive effect of calcium and vitamin D
on femoral neck BMD in community
dwelling men aged 60 years and older.
In one study." men were randomised for
four years to daily calcium 750 mg, 25
hydroxyvitamin D3 15 ug or placebo,
while in the other study" men were ran-
domised for three years to either daily
calcium500mg and vitamin D3 700 units
or placebo. In a third RCT" (E2). no
beneficial effect on either radial or
spinal BMD was found in a younger
cohort (41 treated and 36 controls) who
were treated for three years with dailv
calcium 1000 mg and vitamin D3 1000
units. There are no RCTs assessing
BMD changes in men with osteoporosis
treated with calcium and vitamin D3
alone.
Until studies which are powered ade-
quately to predict fracture prevention
are presented, daily supplementation
with calcium (1500 mg) and vitamin D3
(400 units if serum 25 hydroxyvitamin D
levels less than 40 nrnol/L) must be con-
sidered an important adjunct to other.
therapeutic interventions such as alen-
dronate, etidronate or testosterone.
Calcitriol is the active hormonal form of
vitamin D and has been approved for
the treatment of osteoporosis in men
with fracture (PBS authority required).
This form of therapy is not common
practice in other countries. In a small
cohort of men with cirrhosis" (E4). cal-
citriol prevented spinal bone loss over
12 months. In the only published RCT in
men with osteoporosis" (20 treated and
19 controls, two year study, E3). cal-
citriol (0.25 ~g twice daily) was no better
than calcium (1000 mg daily) alone for
the prevention of fractures. Bone
mineral density remained unchanged in
the calcitriol treated subjects, but
increased by 2-3 % in the calcium
treated subjects.
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SUMMARY OF
IMPORTANT POINTS
.. "'Lifestyle changes together with
:""::daily:calcium supplementation
:'--(1500'rilgr, 'and vitamin D3
(400 units) and if required, serum'
"''''25 hydroxyvltamin D <40 -nmol/L
".. should be considered in addition to
...~ the therapeutic regimen used to
~._. -treat osteoporosis; .
..:--.-'S:p:ecialist ~eferrar- may be" ~ -
I, necessary for.patlents with ...
:-.'. "complex medical .problerns, severe
____osteoporosisvside effects from"
:~:=_,-medication: ,qr for those who do
::":':not -respond.to .the first line
_ --- ~:~-~·~~_?_~0_~~_;~;:~~2~:~~_~·:.-~~ ....~,~_~~._~-:~~,-:-; ,
--~·_·_~~~~Sub~utaneous:~pa"rathY;:Ofd-h()mlO.ne·
byinjectiorri1oidsgreat-promise for
the future.. but will probably'be· .
restricted to a srnatl group of men'
- :·~-~-:-Witti -severe disease who continue
to fracture despite treatment with'
... ~,__, __new ~o~!'t.blS'phosphonates.
References areavailable for this article. -




It is currently unknown what percent- -
ages of men with osteoporosis are
receiving therapy. The present recom- •.Alendronate, followed by cyClical
mendation is to treat all men with BMD etidronate is the treatment of' .
t-score values less than ,-2.5 and. with.a . :~~:_choicecforom""cwitn'P?te_oP.Q,o.~iL-- __
history of osteoporotic fractures." " . 'and fractures:':· . .:~ -; ...::- :_.:...-
At present RCTs suggest that alen- .' • Tes~~steronerePla~emen~ therapy
dronate, followed by cyclical etidronate tslndlceted.tn hypogonadal.men., ••·
are the drugs of choice for men with"-' =C--pT~~hting:with:osteoporosis:-:~--=--CC
osteoporosis. General measures together '.- 30::60% ~f,mE;;;"with spinal
with adequate calcium and vitamin D fractures have another illness
supplements (if required) are always rec- contributing to their bone disease,
ommended. Testosterone replacement so 'in~esti'gation-and treatment 01
therapy is indicated in men with hypogo.underlying medical conditions is
..., __vital...,... _.,
nadism (serum total testosterone
concentration less than 8 nmol/L).
Secondary causes of osteoporosis
should always be defined and specific
disease processes treated appropriately.
Specialist referral may be necessary for
patients with complex medical problems,
severe osteoporosis. side effects from med-
ication, or for those who do not respond
to the first line measures (Table 2).
and spinal BMD in 17 men with idio-
pathic osteoporosis in two other RCTs
(E3).~"
Parathyroid hormone administered
by subcutaneous injection (RCT," 10
men versus 13 controls, E2) significantly
increased lumbar spine BMD by 13.5%
and femoral neck BMD by 2,9% over an
18 month study period (P<O,OOl and
P<0.05 versus controls respectively).
The role of growth hormone and
insulin growth factor therapies in male
osteoporosis remains unproven. In one
RCT" (21 elderly men aged 60 years and
older), spinal BMD increased by 1.6%
after six months of subcutaneous growth
hormone therapy (0.03 mg/kg every
three week, E3), The value of fluoride
and strontium therapies in male osteo-
porosis should be considered as
experimental only.
Monitoring therapy
After initiation of therapy, it is impor-
tant to monitor patients" to ensure that
bone loss is controlled. Serial dual
energy X-ray absorbtiometry measure-
ments are useful for monitoring the
efficacy of therapy because of their
excellent precision, convenience and
rapid scanning times.v" It is recorn-
mended that BMD should be performed
at baseline and after one year of initiat-
ing therapy. Thereafter, biannual DXA
assessments are usually carried out to
monitor response to therapy. Repeat
measurements should be performed on
the same machine for monitoring.
Absolute BMD values (in g/cm') and
not t-score values should be compared
with repeated measurements. A positive
response is regarded as a change in
BMD equal to twice the precision error
of the machine (usually 1% for the
lumbar spine and 0.9% for the total
femoral neck BMD).~ Biochemical mea-
surements of bone turnover" may
become useful in the future for the man-
agement of the individual patient, but
their role has yet to be established.
Australian Family Physician Vol. 30, No.8, August 2001 • 791
